Kirkland Advises MicroPort CardioFlow on Proposed Merger with MicroPort CRM
Kirkland & Ellis advised MicroPort CardioFlow Medtech Corporation (MicroPort CardioFlow) (2160.HK) on its proposed merger with MicroPort Cardiac Rhythm Management Limited (MicroPort CRM). The transaction is subject to customary closing conditions.
MicroPort CardioFlow is a medical device company focusing on the R&D and commercialization of innovative transcatheter and surgical solutions for structural heart diseases dedicated to providing universal access to state-of-the-art total solutions to physicians and patients for the treatment of structural heart diseases. MicroPort CRM is principally engaged in the cardiac rhythm management (CRM) business focusing on solutions for the management of cardiac rhythm disorders. The transaction is a landmark deal in the Hong Kong biotech market. It represents one of the very few very substantial acquisitions announced to date by a company listed under Chapter 18A of the Hong Kong Listing Rules.
Read the transaction announcement here
Kirkland has a long-standing relationship with the MicroPort group, having provided comprehensive legal services to both MicroPort Scientific Corporation (0853.HK) and MicroPort CardioFlow. The Firm has served as MicroPort CardioFlow’s annual compliance counsel since its IPO in 2021. This transaction builds on Kirkland’s deep experience in the sector, which includes advising MicroPort Scientific Corporation on its earlier acquisition of the CRM business. These transactions have demonstrated our full-service legal capabilities in serving leading healthcare companies on their most complex and strategic transactions.
The Kirkland team included corporate lawyers Mengyu Lu, Joey Chau, Brian Ho, George Zheng, Leo Zhou, Chuanwen Wang and Gary Chan.
